Targeting the endocannabinoid system showed promise for HIV-related nerve pain in preclinical studies and two clinical trials
A systematic review found that preclinical studies consistently support endocannabinoid system modulation for HIV-related neuropathic pain, and two clinical trials showed smoked cannabis was more effective than placebo.
Quick Facts
What This Study Found
10 preclinical studies found that endocannabinoids, CB2-selective agonists, and FAAH inhibitors prevented or reversed HIV-associated neuropathic pain. Two completed clinical trials showed smoked cannabis was more effective than placebo. One trial of cannabidivarin (which does not activate cannabinoid receptors) did not reduce HIV neuropathic pain.
Key Numbers
13 studies included. 10 preclinical studies: multiple ECS-targeting compounds effective. 2 clinical trials: smoked cannabis superior to placebo. 1 clinical trial: cannabidivarin not effective. CB2-selective agonists (AM1710, JWH015, JWH133, Gp1a, but not HU308) effective preclinically.
How They Did This
Systematic review searching PubMed, Google Scholar, ClinicalTrials.gov, and EU trial registries for studies on HIV-associated neuropathic pain and endocannabinoid system modulation. 13 articles met inclusion criteria (10 preclinical, 3 clinical).
Why This Research Matters
HIV-associated neuropathic pain affects many patients and has few effective treatments. This review consolidates evidence that the endocannabinoid system is a viable therapeutic target, with some clinical validation.
The Bigger Picture
HIV-associated neuropathic pain remains undertreated. The consistent preclinical evidence and early clinical support suggest non-psychoactive cannabinoid-based treatments could eventually become options, particularly CB2 agonists and FAAH inhibitors.
What This Study Doesn't Tell Us
Only 3 clinical studies met criteria, all with small samples. Smoked cannabis has significant delivery limitations. The preclinical-to-clinical translation gap remains large. Most preclinical models used antiretroviral-induced rather than virus-induced neuropathy.
Questions This Raises
- ?Could non-smoked cannabis formulations (oral, topical) be effective for HIV neuropathic pain?
- ?Would CB2-selective agonists provide pain relief without psychoactive effects in patients?
- ?How do antiretroviral regimen changes affect the need for pain treatment?
Trust & Context
- Key Stat:
- 10 of 10 preclinical studies showed ECS-targeting compounds effective for HIV pain
- Evidence Grade:
- Systematic review with consistent preclinical results and limited but positive clinical data. Small number of clinical trials limits overall evidence strength.
- Study Age:
- 2021 systematic review covering studies through December 2020.
- Original Title:
- Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
- Published In:
- IBRO neuroscience reports, 10, 109-118 (2021)
- Authors:
- Aly, Esraa(2), Masocha, Willias(3)
- Database ID:
- RTHC-02959
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does cannabis help HIV-related nerve pain?
Two clinical trials found smoked cannabis more effective than placebo for HIV neuropathic pain. However, a non-receptor-activating cannabinoid (cannabidivarin) was not effective, suggesting cannabinoid receptor activation is needed.
Are there non-psychoactive options?
Preclinical studies showed CB2-selective agonists and FAAH inhibitors were effective. These would not produce a "high" and are being developed for potential clinical use, though no clinical trials have been completed yet.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02959APA
Aly, Esraa; Masocha, Willias. (2021). Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.. IBRO neuroscience reports, 10, 109-118. https://doi.org/10.1016/j.ibneur.2021.01.004
MLA
Aly, Esraa, et al. "Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.." IBRO neuroscience reports, 2021. https://doi.org/10.1016/j.ibneur.2021.01.004
RethinkTHC
RethinkTHC Research Database. "Targeting the endocannabinoid system for management of HIV-a..." RTHC-02959. Retrieved from https://rethinkthc.com/research/aly-2021-targeting-the-endocannabinoid-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.